Genmab — November 2018
-
"Novartis is advancing a pipeline of medicines with potential to change the standard of care in high burden disease areas. In multiple sclerosis ….blablabla… Also in MS, OMB157 (ofatumumab) is a next generation B-cell depletor with a potentially favorable safety profile from faster b-cell repletion and preserved immunity, and with a convenient monthly sub-cutaneous dosing."
-
Udstiller lige min manglende indsigt.... Jeg forstår simpelthen ikke. hvad godt der kan komme ud af at lade (i dette tilfælde) kineserne "lege" med Genmab's patenterede Duobody. Som JvdW nævnte i Aarhus?..... Tænker at hvis man sidder på en teknologi der kan blive epokegørende. Så beskytter man vel teknologien så godt som overhovedet muligt??
-
Det har aldrig været hensigten, at Duobody kun skulle være til intern brug. Genmab inviterer ligefrem: http://www.genmab.com/duobody/open-innovation
-
Hvad ser i af muligheder i Genmab, hvis man tænker langsigtet? Hvad synes i om kursen lige pt. (skal man købe eller vente)?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind